Winship researchers will share scientific advances and clinical updates in blood diseases at the global 65th Annual Meeting of the American Society of Hematology in San Diego, Dec. 9-12.
Researchers from Winship Cancer Institute of Emory University will share scientific advances and clinical updates in blood diseases at the global 65th Annual Meeting of the American Society of Hematology in San Diego, Dec. 9-12, 2023.
With more than 18,000 members from nearly 100 countries, ASH is the world's largest professional society serving clinicians and scientists who are working to conquer blood diseases.
"Once again this year, Emory Hematology will play a prominent role at ASH," said Winship physician-researcher David A. Frank, MD, PhD, director of the Division of Hematology in Emory University School of Medicine’s Department of Hematology and Medical Oncology. "Both our clinical investigators and our lab-based faculty will be presenting significant advances related to the treatment of blood cancers and other blood disorders. We will have presentations by some of our advanced practice providers, reflecting the close teamwork we have in both patient care and clinical research. In addition, some of our presentations will be delivered by Emory medical students and graduate students, reflecting the significant role we play in training the next generation of hematologists."
Winship presenters will participate in 45 sessions, beginning with pre-conference workshops and symposia on Dec. 8. Oral and poster presentations will describe emerging pre-clinical, epidemiological and clinical hematologic data from Winship teams and colleagues from Emory University School of Medicine, Georgia Institute of Technology and Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta.
Research selected for presentation at ASH represents some of the latest data from Winship-led studies in blood malignancies and benign blood diseases, including pioneering work in areas such as: early phase and investigational therapies; health services and quality improvement; outcomes research; novel biomarkers for treatment guidance; and emerging tools, techniques and artificial intelligence (AI) in hematology.
